Botanical Drug Market to Reach $46.0 Billion by 2035, Supported by Regulatory Recognition

Global botanical drug market was valued at $23.2 billion in 2025 and is expected to reach $46.0 billion by 2035, registering a CAGR of 7.1% over the forecast period (2026-2035). The market continues to expand as regulatory frameworks and public health agencies increasingly recognize the role of plant-based therapies in addressing chronic and lifestyle diseases. Treatments derived from plants, algae, and fungi are subject to formal drug evaluation processes in major markets. For instance, the US Food and Drug Administration defines a botanical drug product as a therapy intended for diagnosing, treating, preventing, or mitigating disease that consists of vegetable materials, including plant parts, algae, or macroscopic fungi, and issues specific guidance to support development and quality standards.

Browse the full report description of “Global Botanical Drug Market Size, Share & Trends Analysis Report By Source (Plant, Algae and macroscopic fungi), By Dosage form (Tablets, Injection and Pills), and By Therapeutic application (Central nervous system, Cardiovascular Disease, Respiratory Disease and Others) Forecast 2026-2035” of https://www.omrglobal.com/industry-reports/botanical-drug-market

Government support for research, clinical validation, and standardized production is rising in North America, Europe, and key Asia Pacific nations, where initiatives are underway to integrate traditional botanical medicines into regulated healthcare pathways and encourage scientific evidence generation. Emerging economies are also strengthening frameworks around natural product therapeutics, with national health policies increasingly incorporating phytomedicines and traditional systems of medicine to improve access and safety.

Innovation Leaders Shaping the Botanical Drug Market

The key players in the botanical drug market include Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson Co., Sanofi SA, Takeda Pharmaceutical Co., Ltd., among others. These companies are driving innovation in botanical drug development through advanced extraction and purification techniques, standardized plant-based formulations, and improved bioavailability across oral and injectable dosage forms. Their focus on clinical validation, regulatory compliance, and scalable manufacturing is supporting the adoption of botanical therapies across central nervous system, cardiovascular, and respiratory disease indications in global healthcare markets.

• In December 2025, DeFloria Inc., a botanical drug developer, emphasized the impact of a US presidential executive order reclassifying cannabis from Schedule I to Schedule III. This change provides clearer regulatory pathways for botanical cannabinoid drugs and supports DeFloria’s FDA botanical drug development for autism-related irritability.
• In September 2025, Jyong Biotech’s plant-derived investigational drug BOTRESO was recognized with a major innovation award at the 2025 Taipei Biotech Awards, highlighting progress in oral botanical therapies for urinary disorders and underscoring the industry’s growing emphasis on clinically validated natural drug development.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Source
  • By Dosage Form
  • By Therapeutic Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson Co., Sanofi SA, Takeda Pharmaceutical Co., Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Botanical Drug Market Report Segment

By Source

• Plant
• Algae
• Macroscopic Fungi

By Dosage Form

• Tablets
• Injection
• Pills

By Therapeutic Application

• Central nervous system
• Cardiovascular disease
• Respiratory disease
• Others

Global Botanical Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/botanical-drug-market